TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8509566
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (initial dose 20 mg followed by 20 mg three times daily)
Study: 3030173
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (2.7 g eicosapentaenoic acid and 1.8 g docosahexaenoic acid in 15 MAX-EPA capsules)
Study: 29802852
Drug: Placebo (identical-appearing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical-appearing capsules)
Study: 24205951
Drug: 5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/day of xylitol (5 lozenges of 1 g each, spaced throughout the day)
Study: 15867235
Drug: Vaccine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine plus radiotherapy
Study: 10594393
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (10 mg/kg per day in two divided doses for 1 month)
Study: 8911886
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release fluphenazine (12 mg)
Study: 8911886
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release fluphenazine (12 mg)
Study: 8911886
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus fluphenazine (2.5 mg)
Study: 27481855
Drug: Propofol dosing
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol dosing based on total body weight
Study: 27481855
Drug: Propofol pharmacodynamics
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol pharmacodynamics (PD) measured by the bispectral index
Study: 22829102
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg/day from cycle day 3 to 7
Study: 22829102
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 100 mg/day from cycle day 3 to 7
Study: 17599856
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 10,000 U once weekly (QW)
Study: 15727086
Drug: Extensive, ambulatory,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extensive, ambulatory, non‐pharmacological obesity treatment programme
Study: 12174105
Drug: Combined formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined formulation once daily
Study: 12174105
Drug: Combined formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined formulation twice daily
Study: 12174105
Drug: Calcipotriol twice
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol twice daily
Study: 8873656
Drug: Streptokinase plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase plus intravenous heparin
Study: 8873656
Drug: Streptokinase plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase plus subcutaneous heparin
Study: 7642857
Drug: Accelerated recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated recombinant tissue-type plasminogen activator (rt-PA) plus intravenous heparin
Study: 7642857
Drug: Streptokinase and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase and rt-PA plus intravenous heparin
Study: 1124659
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg iron as ferrous carbonate once daily
Study: 1124659
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg iron as ferrous carbonate once daily
Study: 30893060
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT)-based multimodal pain rehabilitation program (PRP)
Study: 23490405
Drug: Carotid endarterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid endarterectomy + optimal medical therapy
Study: 23288035
Drug: TYR-free amino
Normalized name: Tyr
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TYR-free amino acid mixture (isoleucine 15 g, leucine 22.5 g, valine 17.5 g, lysine 17.5 g, methionine 5 g, threonine 10 g, tryptophan 2.5 g)
Study: 23288035
Drug: Balanced mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced mixture (BAL; TYR-free plus 12.5 g tyrosine and 12.5 g phenylalanine)
Study: 18095022
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (50 mg)
Study: 16543255
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 100 mg/day + Dexamethazone 2 mg/day
Study: 16543255
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 100 mg/day + Placebo (folic acid tablets)
Study: 10793594
Drug: i.v. tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. tramadol 2 mg kg‐1 (n = 9)
Study: 10793594
Drug: caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: caudal epidural tramadol 2 mg kg‐1 (n = 5)
Study: 8614385
Drug: IV Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Methotrexate (MTX) 500 mg/m2 infused over 24 hours, three times during consolidation and every 6 weeks during maintenance
Study: 8614385
Drug: Oral Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Methotrexate (MTX) 20 mg/m2/week
Study: 8614385
Drug: Both IV
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both IV and oral MTX
Study: 28698881
Drug: Nonselective beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonselective beta-blockers (propranolol or carvedilol) for 4 weeks
Study: 24268395
Drug: Catheter-directed foam
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter-directed foam sclerotherapy (CDFS) with 8 mL of 2% polidocanol-foam (EasyFoam) after perivenous tumescent application.
Study: 24268395
Drug: Catheter-directed foam
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter-directed foam sclerotherapy (CDFS) without pre-treatment size reduction.
Study: 19631847
Drug: Oral analgesics
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral analgesics
Study: 17448944
Drug: Twinrix vaccine
Normalized name: TWINRIX vaccine 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twinrix vaccine
Study: 9885411
Drug: 0.05% all-trans-retinoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% all-trans-retinoic acid (RA) cream
Study: 9885411
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of RA or SA with sodium lauryl sulfate (SLS)
Study: 7617817
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ACTH
Study: 1975483
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine containing 5, 10, or 15 micrograms of epinephrine during saline infusion
Study: 1975483
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine containing 5, 10, or 15 micrograms of epinephrine during esmolol infusion
Study: 1975483
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine containing 5, 10, or 15 micrograms of epinephrine after propranolol injection
Study: 352372
Drug: Morphine 10
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 10 mg i.v.
Study: 7055528
Drug: Buprenorphine 0.3
Normalized name: buprenorphine 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.3 mg i.v.
Study: 23824662
Drug: sugammadex 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugammadex 4 mg/kg
Study: 23436818
Drug: ACR Top
Normalized name: ACR-16
DrugBank: ACR-16 (DB05371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACR Top 5 list items (relating to antinuclear antibodies, Lyme disease, magnetic resonance imaging, bone absorptiometry, and biologic therapy for rheumatoid arthritis)
Study: 21980765
Drug: Nitazoxanide (NTZ)
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide (NTZ) 500 mg tablets twice daily for 6 months
Study: 19166660
Drug: Diuretics and
Normalized name: Low-ceiling diuretics and potassium-sparing agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics and oxygen supplementation
Study: 2781492
Drug: Absorbed dose
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absorbed dose of ionizing radiation <80 Gy (Group I)
Study: 2781492
Drug: Absorbed dose
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absorbed dose of ionizing radiation >100 Gy (Group III)
Study: 697431
Drug: 5,000 USP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 USP units of sodium heparin
Study: 30658622
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy (SMT) group 1: 135N peak force, 125ms impulse duration, 920N/s rate of force application
Study: 30658622
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy (SMT) group 2: 250N peak force, 125ms impulse duration, 1840N/s rate of force application
Study: 30658622
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy (SMT) group 3: 250N peak force, 250ms impulse duration, 920N/s rate of force application
Study: 26162785
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion of 0.3 μg/kg/h
Study: 17645250
Drug: Local blocking
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local blocking therapy (Control group II)
Study: 15898130
Drug: Proton-pump inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-pump inhibitors (PPI)
Study: 7749170
Drug: Navoban (tropisetron)
Normalized name: benzocaine / trimethobenzamide hydrochloride Rectal Suppository [Navogan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navoban (tropisetron) administered at 0.2 mg/kg (maximum 5 mg daily)
Study: 31358017
Drug: Robot-assisted gait
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted gait training combined with conventional physical therapy (RAGT+CPT)
Study: 31358017
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (CPT+CPT)
Study: 21448303
Drug: Bone health
Normalized name: Caltrate Bone Health 600+D3 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone health plan with 1,000 IUs of vitamin D(3) and 750 mg of plant-sourced calcium for one year
Study: 11512037
Drug: Memantine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (60 mg PO)
Study: 11512037
Drug: Naloxone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.4 mg, IM)
Study: 8276058
Drug: Moexipril 15
Normalized name: moexipril 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril 15 mg o.d. with warfarin
Study: 25908321
Drug: Buprenorphine/naloxone tapering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone tapering strategies
Study: 23514728
Drug: 50% rapid-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% rapid-acting insulin dose postexercise
Study: 23514728
Drug: Full rapid-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full rapid-acting insulin dose postexercise
Study: 23514728
Drug: 75% rapid-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75% rapid-acting insulin dose postexercise
Study: 21999663
Drug: Hydrocortisone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (200 mg.day‐1 for 7 days, 100 mg on days 8-9 and 50 mg on day-10) with fludrocortisone (50 μg for 10 days)
Study: 10926942
Drug: Fluoxetine (FLX)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FLX) 20 mg/d for 6 weeks
Study: 3740651
Drug: Albuterol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (4 mg)
Study: 15673893
Drug: Spinal 2-chloroprocaine
Normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal 2-chloroprocaine (2-CP) 30 or 40 mg, with or without fentanyl (10-20 microg)
Study: 12006131
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg twice daily during the first week of each month
Study: 30388
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three beta-blockers
Study: 22194637
Drug: Human papillomavirus‐16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine
Study: 15860688
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone (CRH); specific concentration not mentioned; effects observed in both pregnant and nonpregnant myometrium.
Study: 9431826
Drug: Buffered ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buffered ketoprofen (12.5 mg)
Study: 9119100
Drug: Intravenous albumin
Normalized name: albumin human, USP Injection [Albuminar]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous albumin (10 g 20%, 50 ml) infusion before oocyte pick-up
Study: 1949135
Drug: Intramuscular sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular sulfadoxine-pyrimethamine (25 mg/kg plus 1.25 mg/kg in a single dose)
Study: 1949135
Drug: Intramuscular quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular quinine (10 mg/kg 8-hourly for at least 3 days followed by oral quinine to complete 7 days)
Study: 31694220
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (ZS) 30 mg/day
Study: 31694220
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (ZS) 15 mg/day
Study: 28756579
Drug: Operational multidisciplinary
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Operational multidisciplinary antibiotic team (intervention group)
Study: 28756579
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no operational multidisciplinary antibiotic team)
Study: 26445139
Drug: Inhaled loxapine
Normalized name: loxapine Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled loxapine (10 mg)
Study: 26501204
Drug: Inhaled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo + oral moxifloxacin (400 mg; positive control)
Study: 18842612
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (Pw)
Study: 17455445
Drug: SM2: application
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM2: application of a methyl methacrylate‐based bonding agent (Vitacol)
Study: 17455445
Drug: SM1: No
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM1: No surface treatment (control)
Study: 14985218
Drug: Zinc treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc treatment
Study: 82355
Drug: Zinc +
Normalized name: GNP Cal Mag Zinc + D Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc + vitamin A treatment
Study: 14985218
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A treatment
Study: 21243736
Drug: VeraTran (verapamil/trandolapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: VeraTran (verapamil/trandolapril 180 mg/2 mg daily)
Study: 21243736
Drug: Trandolapril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (2 mg daily)
Study: 15078378
Drug: Caudal tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal tramadol (2 mg.kg(‐1) after surgery)
Study: 15078378
Drug: Caudal tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal tramadol (2 mg.kg(‐1) before incision)
Study: 15078378
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol (2 mg.kg(‐1) after surgery)
Study: 15078378
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol (2 mg.kg(‐1) after anaesthesia induction)
Study: 9267140
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral etoposide (25 mg) with concurrent radiation therapy (ERT group)
Study: 9267140
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy alone (RT group)
Study: 26266659
Drug: Gln plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gln plus ED (total oral intake of 8862 mg Gln/day)
Study: 26266659
Drug: Gln (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gln (oral intake of 8910 mg Gln/day)
Study: 23044768
Drug: Andrographis paniculata
Normalized name: Andrographis paniculata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographis paniculata extract (HMPL-004) 1,200 mg daily
Study: 23044768
Drug: Andrographis paniculata
Normalized name: Andrographis paniculata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographis paniculata extract (HMPL-004) 1,800 mg daily
Study: 10725619
Drug: Amifostine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (150 mg/m²) administered 15-30 min prior to each radiation session
Study: 1526081
Drug: Enoxacin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin alone (400 mg)
Study: 1526081
Drug: Enoxacin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin after ranitidine (50 mg IV)
Study: 1526081
Drug: Enoxacin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin after combined ranitidine and pentagastrin treatment
Study: 30901130
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg ketamine
Study: 12107551
Drug: IST-622 (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: IST-622 (280 or 525 mg/m² once daily for five consecutive days)
Study: 9730857
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E administration (500 i.u. twice daily for 4 weeks)
Study: 24894197
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E administration
Study: 8014585
Drug: lovastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin (40 mg b.i.d) + low cholesterol diet (mean 246 mg/day)
Study: 8014585
Drug: lovastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin (40 mg b.i.d) + high cholesterol diet (mean 1071 mg/day)
Study: 2900132
Drug: Urapidil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (25 mg, increased to 50 mg if necessary)
Study: 31019123
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg/day
Study: 28545498
Drug: SCOOT program
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCOOT program (6 weeks of one-to-one scooter training by an experienced occupational therapist, training once or twice per week)
Study: 26322280
Drug: Bupivacaine 1
Normalized name: bupivacaine 132 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 1 mg/kg
Study: 26322280
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bupivacaine-tramadol
Study: 23434387
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated monovalent H1N1pdm09 vaccine
Study: 23434387
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated trivalent 2009-10 seasonal influenza vaccine
Study: 22097202
Drug: Biantong Huangqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biantong Huangqi Ointment (BHO), one dose daily during remission phase for 1 month
Study: 22097202
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (WM) alone during onset phase
Study: 22097202
Drug: Biantong Huangqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biantong Huangqi Ointment (BHO)
Study: 20924393
Drug: Granular PGX
Normalized name: PGX
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granular PGX (2.5, 5, and 7.5 g) at breakfast
Study: 20924393
Drug: Granular PGX
Normalized name: PGX
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granular PGX (5 g) consumed from -45 to +15 min before and after a meal
Study: 20924393
Drug: Capsules containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing 3, 4.5, and 6 g PGX consumed with the evening meal
Study: 18191645
Drug: Alpha-tocopherol (AT)
Normalized name: alpha tocopherol
DrugBank: alpha-Tocopherol acetate (DB14003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpha-tocopherol (AT) 800 mg/day
Study: 18191645
Drug: Gamma-tocopherol (GT)
Normalized name: gamma-Tocopherol
DrugBank: gamma-Tocopherol (DB15394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-tocopherol (GT) 800 mg/day
Study: 18191645
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AT and GT
Study: 15283007
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg modafinil plus CBT
Study: 15283007
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg modafinil plus contact control (monitor‐only condition)